Form 4 for CALC CalciMedica, Inc.
Accepted 2023-03-27 00:00:00 ET · period of report 2023-03-23 · accession 0001209191-23-021307 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-27 | 2023-03-23 | CALC | Zamiri Parisa | Chief Medical Off | F - Tax | $5.50 | -17.9K | 29.0K | -38% | -$98.5K |
| D | 2023-03-27 | 2023-03-23 | CALC | Zamiri Parisa | Chief Medical Off | D - Sale to Iss | — | +42.8K | 46.9K | +1,040% | — |
| D | 2023-03-27 | 2023-03-23 | CALC | Zamiri Parisa | Chief Medical Off | D - Sale to Iss | — | -42.8K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-23 | F | D | 17,901 | $5.50 | 28,982 | D | — | — | (F2) Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023. |
| 2 | Common | Common Stock | 2023-03-23 | D | A | 42,771 | — | 46,883 | D | — | — | (F1) Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. (F2) Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023. |
| 3 | Derivative | Restricted Stock Unit | 2023-03-23 | D | D | 42,771 | — | 0 | D | — · — to — | 42,771 Common Stock | (F1) Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. |